baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Celldex Therapeutics Inc/ US15117B2025 /

10/18/2024 10:00:00 PM	Chg. -0.4900	Volume	Bid1:55:26 AM	Ask1:55:26 AM	High	Low
28.2500USD	-1.70%	864,609 Turnover: 18.7 mill.	25.0000Bid Size: 1,000	30.6100Ask Size: 100	29.0000	28.0600

GlobeNewswire 8/8 Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 7/29 Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic I...

GlobeNewswire 7/16 Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spo...

GlobeNewswire 6/4 Celldex Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire 6/2 Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolima...

GlobeNewswire 5/15 Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

GlobeNewswire 5/6 Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 4/17 Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chroni...

GlobeNewswire 3/8 Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire 3/5 Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire 3/5 Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Under...

GlobeNewswire 3/1 Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

GlobeNewswire 2/28 Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire 2/26 Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 2/24 Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic S...

GlobeNewswire 2/6 Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire 2/5 Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urti...

GlobeNewswire 12/27/2023 Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

GlobeNewswire 12/7/2023 Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

GlobeNewswire 11/27/2023 Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

GlobeNewswire 11/8/2023 Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire 11/7/2023 Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire 11/6/2023 Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic ...

GlobeNewswire 11/5/2023 Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Mean...

GlobeNewswire 11/2/2023 Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Celldex Therapeutics Inc/ US15117B2025 /

If you wish to receive reply to your feedback, please provide your email address.